StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) company profile

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.86−0.10 (-2.53%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

About Artiva Biotherapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops natural killer cell therapies to treat autoimmune disorders. The company’s primary candidate is AlloNK, an investigational allogeneic natural killer cell therapy currently undergoing clinical development. This lead candidate targets diseases including lupus nephritis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjögren’s disease, and idiopathic inflammatory myopathies. Artiva also maintains early-stage discovery and preclinical programs, as well as collaborative partnerships. Because all assets remain in development, the company has no commercialized products or paying customers, directing its therapies toward patients suffering from autoimmune diseases.

The company maintains its corporate headquarters and principal executive offices in San Diego, California. Its domestic presence includes a manufacturing facility located in San Diego. Artiva conducts its research, operational, and clinical trial activities in the United States without maintaining commercial facilities or global retail branches.

Summary of the business section of Artiva Biotherapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Artiva Biotherapeutics, Inc.
Founded
2019
Headquarters
San Diego, CA
Address
5505 Morehouse Drive 92121
Phone
(858) 267-4467
Employees
104, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Diego, California

Stock & identifiers

Ticker
ARTV
Exchange
Nasdaq
IPO date
Jul 19, 2024
Shares outstanding
49M, Jul 31, 2026
Public float
$15.00M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1817241
CUSIP
04317A107
ISIN
US04317A1079
FIGI
BBG00VPZJ0F9
Share class FIGI
BBG00VPZJ0G8
EIN
86-3614316

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Fred AslanChief Executive Officer, Director1,457,428
Subhashis BanerjeeChief Medical Officer168,738
Jennifer BushCOO, CLO, Compliance Officer357,720
Christopher HoranChief Tech Operations Officer302,321
Gines Diego MirallesPresident & Head of R&D122,500
Heather RaymonSVP, Research and Development148,228
Thad Allen HustonChief Financial Officer220,000
Neha KrishnamohanChief Financial Officer99,356
Thorsten GraefChief Medical Officer80,000
Capital Healthcare Fund LP RADirector17,329,570
Alison MooreDirector–
Elaine K. SorgDirector–
Brian DanielsDirector–
Rajeev M. ShahDirector16,817,573
RA Capital Nexus Fund III, L.P.Director17,283,802
Peter KolchinskyDirector17,242,483
RA Capital Nexus Fund, L.P.Director16,817,543
Ra Capital Management, L.P.Director16,795,919
Daniel G. BakerDirector–
Laura StoppelDirector–
Elizabeth L. HougenDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Fred Aslan
Chief Executive Officer
$665.00K$5.46M$536.28K$14.23K$6.67M-15%
Jennifer Bush
Chief Operating Officer, Chief Legal Officer and Compliance Officer
$520.00K$697.50K$304.98K$14.23K$1.54M+2%
Christopher Horan
Chief Technical Operations Officer
$490.00K$638.24K$287.39K$234$1.42M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 104 full-time employees, 21 of whom held an M.D., Pharm.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 16, 2024ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?